Cargando…
Immunogenicity and clinical features relating to BNT162b2 messenger RNA COVID-19 vaccine, Ad26.COV2.S and ChAdOx1 adenoviral vector COVID-19 vaccines: a systematic review of non-interventional studies
BACKGROUND: Vaccination against Coronavirus disease 2019 (COVID-19) is an important means of controlling the pandemic, however they are expected to stimulate immune responses when administered to confer immunity. In this review, we evaluated the clinical and laboratory features associated with BNT16...
Autores principales: | Iheanacho, Chinonyerem O., Eze, Uchenna I. H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8959558/ https://www.ncbi.nlm.nih.gov/pubmed/35368622 http://dx.doi.org/10.1186/s43094-022-00409-5 |
Ejemplares similares
-
A systematic review of effectiveness of BNT162b2 mRNA and ChAdOx1 adenoviral vector COVID-19 vaccines in the general population
por: Iheanacho, Chinonyerem O., et al.
Publicado: (2021) -
Evaluation of Two-Month Antibody Levels after Heterologous ChAdOx1-S/BNT162b2 Vaccination Compared to Homologous ChAdOx1-S or BNT162b2 Vaccination
por: Barocci, Simone, et al.
Publicado: (2022) -
Comparison of Antibody Response Elicited by ChAdOx1 and BNT162b2 COVID-19 Vaccine
por: Kang, Yu Min, et al.
Publicado: (2021) -
Comparative effectiveness and safety of homologous two-dose ChAdOx1 versus heterologous vaccination with ChAdOx1 and BNT162b2
por: Hermosilla, Eduardo, et al.
Publicado: (2022) -
ChAdOx1-S vaccine for prevention of COVID-19
Publicado: (2021)